A Study of BYL719 in Adult Patients With Advanced Solid Malignancies.
Phase of Trial: Phase I
Latest Information Update: 12 Sep 2017
At a glance
- Drugs Alpelisib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Novartis; Novartis Pharmaceuticals
- 12 Sep 2017 Results assessing food effect on pharmacokinetics of alpelisib and prliminary effecacy (n=33) presented at the 42nd European Society for Medical Oncology Congress
- 26 Jan 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 20 Aug 2015 Planned number of patients changed from 36 to 34 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History